| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elin Byman, Katarina Nägga, Anna-Märta Gustavsson, Johanna Andersson-Assarsson, Oskar Hansson, Emily Sonestedt, Malin Wennströ. Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer's dementia. Alzheimer's research & therapy. vol 12. issue 1. 2021-06-24. PMID:33220711. |
previous studies have shown that copy number variation (cnv) in the alpha (α)-amylase gene (amy1a) is associated with body mass index, insulin resistance, and blood glucose levels, factors also shown to increase the risk of alzheimer's dementia (ad). |
2021-06-24 |
2023-08-13 |
Not clear |
| Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza, Thalia van der Doef, Eleni Frangou, Sharon Love, Gail Busza, Valeria Calsolaro, Stefan Carver, Clive Holmes, Craig W Ritchie, Robert M Lawrence, Brady McFarlane, George Tadros, Basil H Ridha, Carol Bannister, Zuzana Walker, Hilary Archer, Elizabeth Coulthard, Ben Underwood, Aparna Prasanna, Paul Koranteng, Salman Karim, Kehinde Junaid, Bernadette McGuinness, Anthony Peter Passmore, Ramin Nilforooshan, Ajayverma Macharouthu, Andrew Donaldson, Simon Thacker, Gregor Russell, Naghma Malik, Vandana Mate, Lucy Knight, Sajeev Kshemendran, Tricia Tan, Christian Holscher, John Harrison, David J Brooks, Clive Ballard, Paul Ediso. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? Alzheimer's research & therapy. vol 13. issue 1. 2021-06-24. PMID:33597002. |
does insulin resistance influence neurodegeneration in non-diabetic alzheimer's subjects? |
2021-06-24 |
2023-08-13 |
human |
| Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza, Thalia van der Doef, Eleni Frangou, Sharon Love, Gail Busza, Valeria Calsolaro, Stefan Carver, Clive Holmes, Craig W Ritchie, Robert M Lawrence, Brady McFarlane, George Tadros, Basil H Ridha, Carol Bannister, Zuzana Walker, Hilary Archer, Elizabeth Coulthard, Ben Underwood, Aparna Prasanna, Paul Koranteng, Salman Karim, Kehinde Junaid, Bernadette McGuinness, Anthony Peter Passmore, Ramin Nilforooshan, Ajayverma Macharouthu, Andrew Donaldson, Simon Thacker, Gregor Russell, Naghma Malik, Vandana Mate, Lucy Knight, Sajeev Kshemendran, Tricia Tan, Christian Holscher, John Harrison, David J Brooks, Clive Ballard, Paul Ediso. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects? Alzheimer's research & therapy. vol 13. issue 1. 2021-06-24. PMID:33597002. |
type 2 diabetes is a risk factor for alzheimer's disease (ad), and ad brain shows impaired insulin signalling. |
2021-06-24 |
2023-08-13 |
human |
| Carmen Hierro-Bujalance, Carmen Infante-Garcia, Angel Del Marco, Marta Herrera, Maria Jose Carranza-Naval, Javier Suarez, Pilar Alves-Martinez, Simon Lubian-Lopez, Monica Garcia-Alloz. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimer's research & therapy. vol 12. issue 1. 2021-06-22. PMID:32264944. |
both alzheimer's disease (ad) and type 2 diabetes (t2d) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. |
2021-06-22 |
2023-08-13 |
mouse |
| Mai Marie Hol. Insulin as a potent bidirectional regulator of GABAergic signalling in the hippocampus of an Alzheimer's disease mouse model. Acta physiologica (Oxford, England). vol 232. issue 2. 2021-06-22. PMID:33830635. |
insulin as a potent bidirectional regulator of gabaergic signalling in the hippocampus of an alzheimer's disease mouse model. |
2021-06-22 |
2023-08-13 |
mouse |
| Matteo Spinelli, Salvatore Fusco, Claudio Grass. Brain insulin resistance impairs hippocampal plasticity. Vitamins and hormones. vol 114. 2021-06-21. PMID:32723548. |
finally, we reassume the experimental and epidemiological evidence highlighting the critical role of brain insulin resistance at the crossroad between type 2 diabetes and alzheimer's disease. |
2021-06-21 |
2023-08-13 |
Not clear |
| Ayse L Mindikoglu, Mustafa M Abdulsada, Antrix Jain, Jong Min Choi, Prasun K Jalal, Sridevi Devaraj, Melissa P Mezzari, Joseph F Petrosino, Antone R Opekun, Sung Yun Jun. Intermittent fasting from dawn to sunset for 30 consecutive days is associated with anticancer proteomic signature and upregulates key regulatory proteins of glucose and lipid metabolism, circadian clock, DNA repair, cytoskeleton remodeling, immune system and cognitive function in healthy subjects. Journal of proteomics. vol 217. 2021-06-18. PMID:31927066. |
our results showed that intermittent fasting from dawn to sunset for over 14 h daily for 30 consecutive days was associated with an anticancer serum proteomic signature and upregulated key regulatory proteins of glucose and lipid metabolism, insulin signaling, circadian clock, dna repair, cytoskeleton remodeling, immune system, and cognitive function, and resulted in a serum proteome protective against cancer, obesity, diabetes, metabolic syndrome, inflammation, alzheimer's disease, and several neuropsychiatric disorders. |
2021-06-18 |
2023-08-13 |
human |
| Sarathlal K C, Violina Kakoty, Kowthavarapu Venkata Krishna, Sunil Kumar Dubey, Deepak Chitkara, Rajeev Taliya. Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease. ACS chemical neuroscience. vol 12. issue 9. 2021-06-18. PMID:33860663. |
anomalies in brain insulin signaling have been demonstrated to be involved in the pathology of alzheimer disease (ad). |
2021-06-18 |
2023-08-13 |
mouse |
| Anna Litwiniuk, Wojciech Bik, Małgorzata Kalisz, Agnieszka Baranowska-Bi. Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer's Disease. International journal of molecular sciences. vol 22. issue 11. 2021-06-17. PMID:34070553. |
inflammasome nlrp3 potentially links obesity-associated low-grade systemic inflammation and insulin resistance with alzheimer's disease. |
2021-06-17 |
2023-08-13 |
Not clear |
| Manfred Hallschmi. Intranasal insulin. Journal of neuroendocrinology. vol 33. issue 4. 2021-06-15. PMID:33506526. |
two decades of studies in healthy humans and patients have demonstrated that in insulin exerts functional effects on metabolism, such as reductions in food intake and body weight and improvements of glucose homeostasis, as well as cognition, ie, enhancements of memory performance both in healthy individuals and patients with mild cognitive impairment or alzheimer's disease; these studies moreover indicate a favourable safety profile of the acute and repeated use of in insulin. |
2021-06-15 |
2023-08-13 |
Not clear |
| Manfred Hallschmi. Intranasal insulin. Journal of neuroendocrinology. vol 33. issue 4. 2021-06-15. PMID:33506526. |
"brain insulin resistance" is an evolving concept that posits impairments in central nervous insulin signalling as a pathophysiological factor in metabolic and cognitive disorders such as obesity, type 2 diabetes and alzheimer's disease, and, notably, a target of interventions that rely on in insulin. |
2021-06-15 |
2023-08-13 |
Not clear |
| Manfred Hallschmi. Intranasal insulin. Journal of neuroendocrinology. vol 33. issue 4. 2021-06-15. PMID:33506526. |
still, the negative outcomes of longer-term in insulin trials in individuals with obesity or alzheimer's disease highlight the need for conceptual as well as methodological advances to translate the promising results of proof-of-concept experiments and pilot clinical trials into the successful clinical application of in insulin. |
2021-06-15 |
2023-08-13 |
Not clear |
| Sergio T Ferreir. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease. Journal of neuroendocrinology. vol 33. issue 4. 2021-06-15. PMID:33739563. |
brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in alzheimer's disease. |
2021-06-15 |
2023-08-13 |
Not clear |
| Sergio T Ferreir. Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease. Journal of neuroendocrinology. vol 33. issue 4. 2021-06-15. PMID:33739563. |
defective brain insulin signalling, as well as related signalling by insulin-like growth factor 1 (igf-1), is associated with neurological disorders, including alzheimer's disease, suggesting that cognitive impairment could be related to a state of brain insulin resistance. |
2021-06-15 |
2023-08-13 |
Not clear |
| Mario Muñoz-Jiménez, Alí Zaarkti, Juan Antonio García-Arnés, Natalia García-Casare. Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review. Dementia and geriatric cognitive disorders. vol 49. issue 5. 2021-06-14. PMID:33080602. |
considering that alzheimer's disease (ad) and diabetes mellitus share pathophysiological features and ad remains with no cure, antidiabetic drugs like intranasal insulin, glitazones, metformin, and liraglutide are being tested as a potential treatment. |
2021-06-14 |
2023-08-13 |
Not clear |
| Manoj Govindarajulu, Priyanka D Pinky, Ian Steinke, Jenna Bloemer, Sindhu Ramesh, Thiruchelvan Kariharan, Robert T Rella, Subhrajit Bhattacharya, Muralikrishnan Dhanasekaran, Vishnu Suppiramaniam, Rajesh H Ami. Gut Metabolite TMAO Induces Synaptic Plasticity Deficits by Promoting Endoplasmic Reticulum Stress. Frontiers in molecular neuroscience. vol 13. 2021-06-10. PMID:32903435. |
in the current study, we investigated the relationship between tmao and deficits in synaptic plasticity in an alzheimer's model (3×tg-ad) and insulin resistance (leptin deficient db/db) mouse by measuring plasma and brain levels of tmao. |
2021-06-10 |
2023-08-13 |
mouse |
| Ehsan Sharifipour, Soroush Sharifimoghadam, Navid Hassanzadeh, Negin Ghasemian Mojarad, Abdoreza Ghoreishi, Seyyed Amir Hejazi, Kambiz Rohampou. Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease. Acta neurologica Belgica. vol 120. issue 4. 2021-06-08. PMID:30707409. |
altered plasma visfatin levels and insulin resistance in patients with alzheimer's disease. |
2021-06-08 |
2023-08-13 |
human |
| Ehsan Sharifipour, Soroush Sharifimoghadam, Navid Hassanzadeh, Negin Ghasemian Mojarad, Abdoreza Ghoreishi, Seyyed Amir Hejazi, Kambiz Rohampou. Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease. Acta neurologica Belgica. vol 120. issue 4. 2021-06-08. PMID:30707409. |
central insulin resistance is involved in the pathophysiology of alzheimer's disease (ad). |
2021-06-08 |
2023-08-13 |
human |
| Zhijun He, Shuangxue Han, Chong Wu, Lina Liu, Huazhang Zhu, Ang Liu, Qiying Lu, Jingqiang Huang, Xiubo Du, Nan Li, Qinguo Xie, Lu Wan, Jiazuan Ni, Lingling Chen, Xiaogai Yang, Qiong Li. Bis(ethylmaltolato)oxidovanadium(iv) inhibited the pathogenesis of Alzheimer's disease in triple transgenic model mice. Metallomics : integrated biometal science. vol 12. issue 4. 2021-06-03. PMID:31970356. |
vanadium compounds have been reported to mimic the anti-diabetes effects of insulin on rodent models, but their effects on alzheimer's disease (ad) have rarely been explored. |
2021-06-03 |
2023-08-13 |
mouse |
| Hui Lv, Lingjiao Tang, Canshou Guo, Yongming Jiang, Ce Gao, Yifan Wang, Chongdong Jia. Intranasal insulin administration may be highly effective in improving cognitive function in mice with cognitive dysfunction by reversing brain insulin resistance. Cognitive neurodynamics. vol 14. issue 3. 2021-06-02. PMID:32399074. |
it is well known in clinical practice that alzheimer's disease (ad) is closely associated with brain insulin resistance, and the cerebral insulin pathway has been proven to play a critical role in the pathogenesis of ad. |
2021-06-02 |
2023-08-13 |
mouse |